Celgene Corporation (CELG): Today's Featured Drugs Loser

Celgene Corporation ( CELG) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day down 0.4%. By the end of trading, Celgene Corporation fell 45 cents (-0.6%) to $72.93 on average volume. Throughout the day, 3.3 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.8 million shares. The stock ranged in price between $72.75-$73.86 after having opened the day at $73.65 as compared to the previous trading day's close of $73.38. Other company's within the Drugs industry that declined today were: NeurogesX ( NGSX), down 8.8%, Biodel ( BIOD), down 7.7%, Amicus Therapeutics ( FOLD), down 7.4%, and Hemispherx Biopharma ( HEB), down 7.3%.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. Celgene Corporation has a market cap of $32 billion and is part of the health care sector. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Warner Chilcott ( WCRX), up 16.1%, NuPathe ( PATH), up 15.3%, China Shenghuo Pharmaceutical Holdings ( KUN), up 13.5%, and Cleveland BioLabs ( CBLI), up 10.9%, were all gainers within the drugs industry with Merck ( MRK) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).